Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:25602015  

Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypes.

Mark K Santillan | Christopher J Pelham | Pimonrat Ketsawatsomkron | Donna A Santillan | Deborah R Davis | Eric J Devor | Katherine N Gibson-Corley | Sabrina M Scroggins | Justin L Grobe | Baoli Yang | Steven K Hunter | Curt D Sigmund
Physiological reports | 2015

Preeclampsia is a cardiovascular disorder of late pregnancy that is, commonly characterized by hypertension, renal structural damage and dysfunction, and fetal growth restriction. Prevailing etiologic models of this disorder include T-cell dysfunction as an initiating cause of preeclampsia. Indoleamine 2,3-dioxygenase (IDO), an enzyme that mediates the conversion of tryptophan to kynurenine, has been linked to preeclampsia in humans, and is known to regulate T-cell activity and an endothelial-derived relaxing factor. To test the hypothesis that IDO is causally involved in the pathogenesis of preeclampsia, mice deficient for IDO (IDO-KO) were generated on a C57BL/6 background. IDO-KO and wild-type C57BL/6 mice were bred, and preeclampsia phenotypes were evaluated during pregnancy. Pregnant IDO-KO mice exhibited pathognomonic renal glomerular endotheliosis, proteinuria, pregnancy-specific endothelial dysfunction, intrauterine growth restriction, and mildly elevated blood pressure compared to wild-type mice. Together these findings highlight an important role for IDO in the generation of phenotypes typical of preeclampsia. Loss of IDO function may represent a risk factor for the development of preeclampsia. By extension, increased IDO activity, reductions in IDO reactants, or increases in IDO products may represent novel therapeutic approaches for this disorder.

Pubmed ID: 25602015

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NHLBI NIH HHS, United States
    Id: R37 HL048058
  • Agency: NIAID NIH HHS, United States
    Id: T32 AI007260
  • Agency: NICHD NIH HHS, United States
    Id: K12 HD000849
  • Agency: NCATS NIH HHS, United States
    Id: KL2 TR000444
  • Agency: NCRR NIH HHS, United States
    Id: KL2 RR024980
  • Agency: NHLBI NIH HHS, United States
    Id: P01 HL062984
  • Agency: NHLBI NIH HHS, United States
    Id: R00 HL098276
  • Agency: NHLBI NIH HHS, United States
    Id: P01 HL084207
  • Agency: NHLBI NIH HHS, United States
    Id: K99 HL098276

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SigmaStat (tool)

RRID:SCR_010285

Software tool for data graphing and analysis by Systat Software, Inc.

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions